Cost Plus Drugs
Cost Plus Drugs is an online pharmacy launched in January 2022 by Mark Cuban and Dr. Alex Oshmyansky, whose earlier company was founded in 2018. It offers prescription medications using transparent acquisition-cost pricing plus a 15% markup, pharmacy labor and shipping charges. Structured as a public benefit corporation, it seeks to reduce drug costs by working directly with manufacturers and through pharmacy, insurer and employer partners. The company has a Dallas manufacturing facility and a catalog exceeding 1,000 prescription products; availability and final fees vary by medication and order.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-10-29. Score revised 2026-10-29: 12 → 11.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
The online pharmacy launches with about 100 generic drugs priced at manufacturer cost plus 15%, a $3 pharmacy fee and shipping, as a public benefit corporation backed by Mark Cuban. It is a cash-only, direct-to-consumer service whose catalog grows to about 350 unique drugs by the fall, and a June 2022 Annals study estimates $3.6 billion in potential Medicare savings at its prices. Few user-side problems are documented before demand begins to outrun capacity.
Rightway becomes the first PBM to add Cost Plus Drugs to its network, followed by Capital Blue Cross, SmithRx, Blue Shield of California and Select Health, moving the pharmacy from cash-only sales into insured channels. The Team Cuban Card affiliate network, the Yusimry biosimilar and a 2,200-medication formulary widen access. Growth also strains operations: the CEO later described one-to-two-week dispatch delays in late 2022, and the pharmacy labor fee rose from $3 to $5 in September 2023.
Dallas manufacturing starts, weeks after the Cost Plus Marketplace opened to healthcare businesses, bringing hospital sales (Community Health Systems, Penn Medicine) and FDA-coordinated penicillin imports. By December 2024 the CEO reports prescriptions going out in 1.5 days on average. From late 2025 the company also becomes price infrastructure for others, through TrumpRx, Humana's CenterWell, Network Health and Epic, while adding brand drugs such as Eliquis. Customer-service complaints continue, and studies show savings are concentrated in high-cost-sharing fills.
Alternatives
Amazon's mail-order pharmacy shows estimated prices with and without insurance and offers discounts for eligible Prime members. A 2024 study found Amazon often had the lowest prices among the direct-to-consumer pharmacies sampled for expensive generics; prices still vary by drug and coverage. Transfer an existing prescription or ask the prescriber to send one electronically.
Price comparison tool and prescription discount service for participating retail pharmacies. Search for a medication and present the discount code at the pharmacy. In a February 2023 KFF Health News comparison of 211 drug/form/quantity combinations beginning with A in the Washington, D.C., area, at least one GoodRx-listed pharmacy was cheaper than Cost Plus Drugs in 141 cases (about 67%). This was a dated local sample, not a universal price ranking.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (53 events)
Oshmyansky Founds Osh Affordable Pharmaceuticals as PBC
Radiologist Alex Oshmyansky, frustrated by generic drug price gouging exemplified by Martin Shkreli's 5,455% Daraprim price hike, founds Osh Affordable Pharmaceuticals as a public benefit corporation in 2018 after Y Combinator advises against the nonprofit model. The company soon raises approximately $1 million in seed funding.
Cuban Begins Backing Oshmyansky’s Company, Which Later Takes His Name
After receiving Oshmyansky's cold pitch email, Mark Cuban invests a small amount and increases his backing over time. March 2021 reporting places the initial contact around two years earlier; the January 1 date represents that approximate year. The company eventually becomes Mark Cuban Cost Plus Drug Company, PBC, retaining its public benefit mission.
Cost Plus Drugs Online Pharmacy Launches with 100 Generic Drugs
Cost Plus Drugs launches its online pharmacy in January 2022 with approximately 100 generic medications, including drugs for diabetes, asthma and heart conditions. Its transparent formula uses manufacturer cost plus a flat 15% markup and a pharmacist fee. Launch-era reporting documented a $3 pharmacy fee and $5 shipping, with substantial savings on selected drugs compared with quoted retail prices.
Dallas Manufacturing Facility Construction Milestone Celebrated
Cost Plus Drugs celebrates the topping out of its $11 million, 22,000-square-foot pharmaceutical facility at 3015 Taylor Street in Dallas' Deep Ellum neighborhood. The fill-finish facility is designed to formulate, fill and package sterile medicines, with plans for private-label injectables. Construction began in February 2021. Later reporting on robotic and AI technology is retained separately in evidence.
Harvard Study Finds Medicare Could Save $3.6 Billion at Cost Plus Prices
Researchers at Brigham and Women's Hospital publish in the Annals of Internal Medicine finding that Medicare Part D could have saved approximately $3.6 billion (37% of spending) on 77 generic drugs in 2020 if it had purchased at Cost Plus Drugs prices. The study provides rigorous academic analysis of the company's pricing model and its potential systemic impact.
First-Year Sales Estimated at $25 Million as Customer Accounts Pass One Million
September reporting relays Forbes' estimate that Cost Plus Drugs had made at least $25 million in sales during its first nine months. Cuban said the company had more than one million customers. These are a reported estimate and company account, rather than audited financial results. Later CEO testimony about zero marketing spend and word-of-mouth growth is preserved in evidence.
Rightway Becomes First PBM to Add Cost Plus Drugs to Its Network
Rightway announced an integration with Cost Plus Drugs, describing it as the first time a pharmacy benefit manager had added the pharmacy to its network. Rightway PBM members gained direct access to all medications available through Cost Plus Drugs, extending the model from cash-only sales into employer pharmacy benefits.
Rapid Growth Causes One-to-Two-Week Prescription Dispatch Delays
CEO Alex Oshmyansky later said the company was growing 20% to 30% month over month for a prolonged period in late 2022, and that for a period prescriptions were delayed by a week or two while it scrambled to keep pace. The date is approximate: he placed the period in late 2022.
Capital Blue Cross Becomes First Health Plan Partner
Capital Blue Cross in Harrisburg, Pennsylvania becomes Cost Plus Drugs' first health plan partner. Beginning in 2023, members will be able to use their insurance cards at the online pharmacy. At the time it offered approximately 350 unique generic drugs, or nearly 1,000 products when doses are counted separately, priced at manufacturer cost plus a 15% fee. A December 7 report specified that the pharmacy-benefits integration would run through Prime Therapeutics starting January 1, 2023, allowing members to process prescription claims.
Cuban Confirms Minimal Customer Data Collection Policy
Mark Cuban says the prescription data he has is what customers buy and the state they buy from. Healthcare Brew also reports that users provide basic account details and a health survey, and that the privacy policy permits information supplied directly and automatically collected through online services. The separate Paubox customer story documents encrypted communications and is retained in evidence.
SmithRx Partnership Integrates Transparent PBM with Cost Plus Drugs
SmithRx integrates Cost Plus Drugs into its pharmacy network, with access to select medications expected within the next quarter. SmithRx describes its model as 100% transparent and pass-through, contrasting it with legacy spread pricing. Cost Plus Drugs charges acquisition cost plus a 15% markup, dispensing fee and shipping. The later $9.5 million savings result is recorded separately in March 2024.
Team Cuban Card Launches Affiliate Pharmacy Network
Cost Plus Drugs begins building an affiliate retail pharmacy network through the Team Cuban Card, allowing consumers to purchase lower-cost prescriptions locally. STAT reports an initial three dozen participating pharmacies. Subsequent reporting records 80 locations across seven states and more than 2,300 across 38 states and Washington, D.C.; that later expansion is preserved separately in evidence.
Coherus Partnership Brings First Biosimilar to Cost Plus Drugs Platform
Cost Plus Drugs and Coherus BioSciences announce plans to offer Yusimry (adalimumab-aqvh), a Humira biosimilar, starting in July 2023 for $569.27 plus dispensing and shipping fees. The release identifies it as the company's first biologic, extending the catalog beyond small-molecule drugs to treatments for conditions including rheumatoid arthritis and Crohn's disease.
Cost Plus Drugs Raises Pharmacy Labor Fee from $3 to $5
In a June 2 email to customers, Cost Plus Drugs said its per-prescription pharmacy labor fee would rise from $3 to $5 effective September 1, 2023, citing rising pharmacy labor costs. The email gave advance notice and suggested longer supplies to reduce per-prescription fees; the 15% markup was unchanged.
TIME Names Cost Plus Drugs Among 100 Most Influential Companies
TIME includes Cost Plus Drugs in its 2023 TIME100 Most Influential Companies list, in the Disrupters category alongside OpenAI. Stripe also appears on the list, in the Leaders category. TIME's Cost Plus profile highlights direct-to-consumer generic drug sales, transparent pricing, expansion into specialty and branded drugs, and an affiliate retail pharmacy network. The separate first-nine-month sales estimate is recorded in the sales event.
Scripta Insights Partnership Adds Price Comparison Transparency
Cost Plus Drugs partners with Scripta Insights to give patients transparent drug pricing and medication options, helping consumers compare costs across pharmacy channels. The collaboration furthers the company's transparency mission by integrating Cost Plus Drugs pricing data into Scripta's patient-facing price comparison tools.
Blue Shield of California Selects Cost Plus Drugs for Pharmacy Network
Blue Shield of California, a nonprofit insurer with 4.8 million members, announces it will shift most pharmacy services from CVS Caremark, using Cost Plus Drugs and Amazon Pharmacy as preferred pharmacy networks. The move is projected to save $500 million annually on drug costs. Blue Shield employees are first to transition in 2024 before the arrangement expands to members in 2025; CVS Caremark continues specialty-drug services for patients with complex conditions.
Select Health Becomes First Insurer Partner in Intermountain Network
Select Health, a subsidiary of Intermountain Healthcare with over one million members, integrates Cost Plus Drugs into its pharmacy benefits through its PBM Scripius. Members gain access to more than 1,000 prescription products at Cost Plus Drugs' transparent pricing for conditions including high blood pressure, certain cancers, dementia, asthma, and diabetes.
Crohn's & Colitis Foundation Partners for IBD Medication Access
The Crohn's & Colitis Foundation partners with Cost Plus Drugs to improve medication access for IBD patients. Cost Plus Drugs offers Yusimry at $584, compared to $995 at other pharmacies, providing the lowest-cost IBD-specific biosimilar available in the U.S. The partnership helps patients with chronic inflammatory bowel conditions access affordable biologic treatments.
Alto Pharmacy Partnership Adds Courier Delivery for Team Cuban Card
Cost Plus Drugs partners with Alto Pharmacy to enable pickup and courier delivery for Team Cuban Card users in markets where Alto operates. Users can order through Alto's website or app at Team Cuban Card prices plus a delivery fee and choose flexible delivery windows. Oshmyansky describes the benefit of same-day local fulfillment.
Express Scripts Launches ClearNetwork Cost-Plus Pricing Model
Express Scripts announced ClearNetwork, a cost-plus option similar to the Mark Cuban Cost Plus Drugs model, for employers and plans beginning in early 2024. The model estimates each drug’s acquisition cost using the lowest of three benchmarks and adds a flat pharmacy fee and a second fee of 15%.
Expion Health Partnership Extends Cost-Plus Model to Specialty Drugs
Cost Plus Drugs partners with Expion Health to integrate its transparent pricing model into Expion's digital platform for specialty drug cost management. Specialty drugs account for over half of U.S. drug spending despite representing a small fraction of prescriptions, making this expansion significant for Cost Plus Drugs' impact on overall healthcare costs.
Formulary Expands to 2,200 Medications
Cost Plus Drugs expanded its formulary to 2,200 medications in December 2023, adding 1,000 medications, including a number in the rheumatology space. This represents a 22x increase from the initial 100-drug launch catalog in January 2022, reducing the formulary gap for patients needing medications not previously in the catalog.
CVS Announces CostVantage Pharmacy Reimbursement Model and TrueCost PBM Model
CVS announced CostVantage, a retail pharmacy reimbursement model based on drug cost, a set markup, and a pharmacy services fee, and separately introduced TrueCost, a CVS Caremark PBM model with client pricing reflecting net drug cost and visible administrative fees. CVS planned to launch both models in 2025.
Cost Plus Drugs Marketplace Opens to Healthcare Businesses
A TheracosBio release quotes CEO Alex Oshmyansky on the launch of the Cost Plus Drugs Marketplace, a platform giving pharmacies, hospitals, surgery centers and other providers access to prescription and over-the-counter medications from NABP-accredited suppliers. TheracosBio's diabetes drug Brenzavvy became available there at $47.85 per 30-tablet bottle.
CEO Announces Dallas Manufacturing Start at White House Roundtable
At the March 4 White House roundtable on lowering healthcare costs, attended by HHS Secretary Xavier Becerra and FTC Chair Lina Khan, CEO Alex Oshmyansky announces that Cost Plus Drugs will begin Dallas manufacturing that week. Initial commercial batches will include epinephrine and norepinephrine for hospital intensive care patients, with pediatric oncology drugs planned to follow. Cuban criticizes PBM pricing practices at the meeting.
SmithRx and Cost Plus Drugs Report $9.5 Million in Autoimmune Drug Savings
SmithRx announced that its partnership with Cost Plus Drugs had generated more than $9.5 million in savings for clients in the autoimmune category over six months. The companies attributed the savings to sourcing lower-net-cost autoimmune medications, including transitions to more cost-effective alternatives through Cost Plus Drugs.
Community Health Systems Becomes First Hospital System Partner
On March 7, 2024, Community Health Systems announced it would become the first national health system to purchase selected pharmaceutical supplies from Cost Plus Drugs. Initially, CHS-affiliated hospitals in Texas and Pennsylvania would purchase epinephrine and norepinephrine, drugs often used in emergency departments and intensive care units.
Cost Plus Drugs Ships First Dallas-Manufactured Medicines to Hospitals
Cost Plus Drugs begins shipping its first batches of epinephrine and norepinephrine to 10 hospitals in Texas and Pennsylvania, according to Bloomberg reporting relayed by Entrepreneur. Manufacturing began the previous month in Dallas, and the drugs faced national shortages. The facility's rapid-change robotic and AI technology is documented separately in evidence.
JAMA Study Quantifies Patient-Level Savings Across Insurance Types
A JAMA Health Forum economic evaluation estimated potential out-of-pocket savings by comparing 2019 prescription data with Cost Plus Drugs prices from March 2023. Median estimated savings were $4.96 per prescription and $6.08 for uninsured patients. Potential savings appeared in 11.8% of weighted fills overall; for most patients, using health insurance was less expensive. The study estimated potential savings rather than measuring actual savings.
CHS Expands Partnership to All 71 Hospitals with Twelve Initial Drugs
Community Health Systems expands its Cost Plus Drugs purchasing partnership across approximately 71 affiliated hospitals. Hospitals will begin by purchasing twelve drugs from the marketplace, including antibiotics and chemotherapy anti-nausea medications. The companies expect initial annual savings of several hundred thousand dollars, potentially rising as more drugs are approved for purchase.
FTC Interim Report Documents PBM Market Concentration and Conduct
The FTC releases an interim report finding that the six largest PBMs manage nearly 95% of U.S. prescriptions and documenting self-preferencing, unfair contract terms, and practices limiting generic and biosimilar access. The findings concern industry conduct and are consistent with concerns Cuban raised; they are not an FTC endorsement or evaluation of Cost Plus Drugs.
Cost Plus Drugs Secures Temporary Penicillin Importation for Shortage Relief
Cost Plus Drugs works with the FDA to temporarily import penicillin from Portugal's Laboratórios Atral to address the U.S. shortage. D Magazine reports plans for 10,000 vials and the company's claim that the price would fall from $500 to less than $15 per unit. The imported Lentocilin is a foreign product permitted temporarily during the shortage, rather than an FDA-approved drug.
Cuban Announces Plan to Publish All Customer Contracts
Mark Cuban tells Jon Stewart on The Daily Show that Cost Plus Drugs will begin publishing all of its customer contracts online, stating 'Never before has it been done where, for my companies, we're saying if you want to do business with us, we're going to publish them and put them online for anybody to see all of our pricing.' The announcement proposes making business pricing visible to prospective customers.
Penn Medicine Partners to Source Generic Drugs Through Cost Plus
Penn Medicine partnered with Cost Plus Drugs through its Cost Plus Marketplace to source the top 100 most frequently dispensed generic drugs for its retail pharmacy network, which fills over 1.5 million prescriptions annually across 16 locations. The selection includes antibiotics, cancer treatments, blood thinners, and asthma medications. In a December 11 report, WHYY attributed to Penn Medicine chief pharmacy officer Nishaminy Kasbekar plans to eventually transition all generic medication prescription supply to the Cost Plus Drugs marketplace, while continuing to use other suppliers in the meantime.
CEO Reports Prescriptions Ship in 1.5 Days on Average
In a December 2024 interview, CEO Alex Oshmyansky said the company was in a much better place operationally and that prescriptions went out in a day and a half on average, contrasting this with the one-to-two-week delays of late 2022. This is the company's own account, not an independent audit.
CVS Contracts All Commercial Pharmacy Prescriptions Through CostVantage
CVS Health announced that all commercial prescriptions dispensed at CVS Pharmacy were contracted through its CostVantage reimbursement model starting in 2025, using drug acquisition cost plus a defined markup and a dispensing fee. This completes the cost-based model CVS announced in December 2023; it does not establish that Cost Plus Drugs caused the change.
9amHealth Partnership Offers Affordable Obesity Medications to Employers
Cost Plus Drugs partners with 9amHealth to offer low-cost oral medications as an option in 9amHealth's obesity program for self-insured employers. The program also offers branded GLP-1 medications through 9amHealth's direct manufacturer partnerships, alongside virtual obesity care, physician consultations, at-home lab testing, and 24/7 clinical support.
Cost Plus Drugs Joins TrumpRx Drug Price Transparency Initiative
At the HLTH 2025 conference, Mark Cuban announces a collaboration between Cost Plus Drugs and the Trump administration's TrumpRx platform. Cost Plus Drugs will provide API access so TrumpRx can pull real-time prescription drug pricing data, enabling consumers to compare prices across pharmacy channels. Cuban states increased volume through TrumpRx will lower acquisition costs and further reduce patient prices.
Mark Cuban Testifies Before Senate Aging Committee on PBM Reform
Mark Cuban testifies before the Senate Special Committee on Aging in a hearing titled 'Modernizing Health Care: How Shoppable Services Improve Outcomes and Lower Costs.' Cuban details how the PBM system drives up drug costs through rebate-driven pricing and calls for systemic reform. Multiple senators highlight PBM monopolies as hurting community pharmacies and patients.
Cost Plus Drugs Adds Starjemza Biosimilar at $1,380/Year
Cost Plus Drugs adds Starjemza (ustekinumab-hmny), a biosimilar of Stelara, to its specialty drug portfolio at $345 per quarter plus shipping, annualized as $1,380 for four quarterly doses. The report compares this with approximately $165,000 per year for Stelara on an eight-week schedule, and competing biosimilars range from $15,000 to $60,000 annually, making Cost Plus Drugs' pricing dramatically lower for patients with psoriasis, Crohn's disease, and ulcerative colitis.
Cuban Urges Trump to Waive FDA Fees to Enable Generic Manufacturing
Mark Cuban publicly calls on the Trump administration to waive the approximately $365,000 FDA abbreviated new drug application fee for generic drugs, stating it is 'the only thing holding us back' from manufacturing 100 generic treatments domestically. Cuban argues the fee waiver would spur U.S. generics manufacturing and further reduce drug prices.
Humana Explores Partnership with Cost Plus Drugs for Employer Programs
At the Forbes Healthcare Summit, Mark Cuban and Humana CEO Jim Rechtin discuss a possible direct-to-employer pharmacy partnership through Humana's CenterWell business. Cuban cites the 160-plus million people insured through employers and criticizes PBM costs. Later MedCity News reporting also describes his concern that employee out-of-pocket spending funds rebates received by employers. The talks are exploratory, not a completed partnership.
Cost Plus Drugs and Alchem Form Essential Medicines Alliance
Cost Plus Drugs and Alchem Laboratories announced a strategic alliance to develop essential medicines and improve supply-chain resiliency. The companies said Cost Plus Drugs would use its manufacturing platform to produce lidocaine and diltiazem, with Alchem providing process development for the active ingredients. The announcement describes intended production, not products already on sale.
Network Health Reports Results of Cost Plus Medicare Advantage Integration
In a March 2026 retrospective, Network Health describes its Cost Plus Drugs integration launched in early 2025, among the first Medicare Advantage arrangements of its kind. The insurer says it built electronic claims integration with Express Scripts and estimates meaningful savings on approximately 65% of covered medications. It also reports 37% enrollment growth to 126,000 Medicare Advantage members; the article discusses multiple drivers and does not establish that Cost Plus alone caused the growth.
Cost Plus Drugs Adds Eliquis at $345 for a 30-Day Supply
The Bristol Myers Squibb-Pfizer Alliance announced a collaboration with Cost Plus Drugs to offer Eliquis (apixaban) on CostPlusDrugs.com. Starting April 27, patients with a prescription could buy a 30-day supply for a total of $345, adding a direct cash-pay option for a major branded anticoagulant.
Humana's CenterWell and Cost Plus Deepen Employer Pharmacy Partnership
Following the December 2025 talks, Humana announced a deepened partnership between CenterWell Pharmacy and Cost Plus Drugs to develop employer prescription solutions. Cost Plus selected CenterWell as a pharmacy partner, and CenterWell will use Cost Plus's SwiftyRx software for order intake, expected to enable home delivery for eligible Humana employees. The employer program was described as intended, not yet launched.
TrumpRx.gov Integrates Cost Plus Discounts in Generic Expansion
The White House announced that TrumpRx.gov would feature more than 600 generic medications and integrate discounts offered by Cost Plus Drugs, Amazon Pharmacy and GoodRx, letting patients compare cash prices at local pharmacies and delivery programs. It follows the October 2025 TrumpRx announcement; the fact sheet does not say all listings are Cost Plus products.
Annals Study Finds Cost Plus Beats Copays Mainly for Higher-Cost Generics
A brief report in Annals of Internal Medicine, summarized by AJMC, matched more than 62 million 2024 commercial generic claims against 2025 Cost Plus prices. Cost Plus offered savings on only 15% of prescriptions overall (median $6), but nearly 80% of the time when cost-sharing exceeded $15, with a median $119 saving above $100. Cash fills do not count toward deductibles or out-of-pocket maximums.
Cost Plus Drugs Imports Lentocilin Again During Bicillin L-A Shortage
A June 17, 2026 notice to healthcare providers, hosted by the FDA, says Cost Plus Drugs is coordinating with the agency to temporarily import Lentocilin (benzathine benzylpenicillin) 1,200,000 units from Portugal's Laboratorios Atral to address U.S. Bicillin L-A shortages, with distribution effective immediately. The notice states the imported product is not FDA-approved.
Cuban Urges Texas Lawmakers to Count Cash Purchases Toward Deductibles
At Texas House hearings on healthcare affordability, Mark Cuban said many Cost Plus customers are insured but come because the cash price is often lower than their plan's price. He proposed counting cash-pay purchases toward deductibles, standardized PBM contracts, public pricing data for taxpayer-funded care, an end to contract gag clauses and stronger enforcement. The hearing date is inferred from the article's Tuesday reference.
Epic Announces Prescription Marketplace Built with Cost Plus Drugs
Epic announced Prescription Marketplace, a planned feature letting clinicians and patients at Epic-using health systems compare pharmacy cash prices with insured prices before a prescription is sent. Epic named Cost Plus Drugs as one of the pharmacies helping build it and said it would release the feature in summer 2027.
Cost Plus Drugs Begins Work on Custom Rare-Disease Medicines
STAT reported that Cost Plus Drugs had received shipments of custom-made DNA-like molecules for two patients with rare diseases at its Dallas plant earlier in 2026, the first test of an effort to commit part of its new plant to individualized rare-disease treatments. No pricing or patient outcomes were reported.
Evidence (50 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (6 entries)
12→11. D6 2→1 (recalibration: no documented manipulative design; residual automated-support friction and privacy-policy permissions fit 0-1, not the 2-3 'minor dark patterns' row). All other dimensions confirmed from criteria; the late-2022 dispatch delays and 2023 $3→$5 pharmacy-fee rise were added as historical facts but fall in the past era and do not move the present. Since Feb 2026: expansion only (Alchem manufacturing alliance, Eliquis at $345/30 days, Humana CenterWell partnership, TrumpRx generic integration, renewed FDA-coordinated Lentocilin import, Epic Prescription Marketplace, rare-disease work, Texas testimony); no lawsuits, enforcement, layoffs, fee changes or breaches found. Trajectory improving→stable (scores unchanged by events over 12 months). Eras: 'Transparent Launch' re-dated 2022-01-01→2022-01-19 (launch), era D1 3→1, D4 3→2, D8 2→1, D9 3→2; 'Insurer Partnerships' re-dated 2023-06-01→2022-09-27 (Rightway first PBM integration, added), D1 2→3 for scaling delays and fee rise; 'Manufacturing Era' re-dated 2024-03-01→2024-03-04 (manufacturing start), relabeled 'Manufacturing and Partner Growth', and merged with 'Industry Disruptor' (2026-02-15 assessment date; TrumpRx and later partnerships did not change which forces drive the score). Uncovered 3+ cell (Insurer Partnerships D9=3) had no supporting events after search; lowered to 2. Category: no issue.
Checked all 9 candidates: 2 restored, 0 partly restored, 6 confirmed removed, 1 already present. RESTORED timeline:update:6 (current index 8): Prime Therapeutics route and January 1, 2023 start, Managed Healthcare Executive, December 7, 2022, https://www.managedhealthcareexecutive.com/view/mark-cuban-s-low-cost-pharmacy-is-making-deals-with-payers. RESTORED timeline:update:30 (current index 34): eventual all-generic prescription-supply plan attributed to Penn pharmacy chief, WHYY, December 11, 2024, https://whyy.org/articles/penn-medicine-mark-cuban-cost-plus-drugs-generic-medications/. Added supporting evidence from Fierce Healthcare (October 6, 2022) and Penn Medicine (December 6, 2024) to retain the original announcement and scope sources after re-sourcing those timeline items. CONFIRMED REMOVED timeline:update:0: D Magazine confirms the early $1 million but not the round participants; Masters of Scale retains the YC financing context already in the narrative, but no established reporting located connecting Luigi Bajetti to that round. CONFIRMED REMOVED timeline:update:4: the publisher release supports the study, not priority as the first rigorous academic validation. CONFIRMED REMOVED timeline:update:16: readable archived Alto release and PYMNTS support courier windows and same-day local fulfillment but no next-day commitment for this partnership. CONFIRMED REMOVED timeline:update:17: original MHE report and AHA comparison support similar pricing, not prior Express Scripts criticism of that mechanism. ALREADY PRESENT timeline:update:37 (current index 42): the underlying employer-rebate concern is already retained as an attributed MedCity News paraphrase; no duplicate restoration or verbatim headline quotation. CONFIRMED REMOVED evidence:update:8: readable Maverick page displays May 8, 2025, not January 1; Forge remains an undated private-status reference. CONFIRMED REMOVED evidence:update:25: LinkedIn is a dynamic company profile without an established January 1, 2025 publication date. Original URLs and Wayback were attempted for all candidates; unavailable archives were not treated as disproof. All restored facts come from fetched pages read this session. No removals or score changes.
Checked 80 original items, including two alternatives, plus all ten summaries/narratives, four eras and identity fields. 16 verified, 35 corrected (19 date-only), 29 re-sourced, 0 removed. No whole invented events found. Strict contradicted named detail: timeline[10] incorrectly grouped Stripe with Cost Plus in TIME100 Disrupters; TIME’s primary list places Stripe in Leaders (https://time.com/collection/time100-companies-2023/). Other unsupported funding/financial/priority claims are not labeled invented. Three evidence additions preserve existing network-expansion, manufacturing-technology and manufacturer-price-comparison details after splitting compound events. No duplicate whole events were found; milestones and evidence intentionally support distinct timeline events. Scores and era dates unchanged.